WHO ICTRP trial
[M20-466] Moderate to Severe Rheumatoid Arthritis: A Phase 2b, Dose-Ranging…
JPRN-jRCT2041210052 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCT2041210052 |
|---|---|
| Public title | [M20-466] Moderate to Severe Rheumatoid Arthritis: A Phase 2b, Dose-Ranging, Safety and Efficacy Study of ABBV-154 |
| Scientific title | [M20-466] A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response to Biologic and/or Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs (b/tsDMARDs) |
| Primary sponsor | Yamazaki Hayato |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Countries | Australia;Japan;Austria;Japan;Canada;Japan;Czech;Japan;France;Japan;Germany;Japan;Greece;Japan;Hungary;Japan;Isreal;Japan;Italy;Japan;Holland;Japan;New… |
| Conditions | Rheumatiod Arthritis |
| Interventions | Experimental: Dose A of ABBV-154 Participants in this group will receive dose A of ABBV-154 subcutaneously (SC) every other week (eow) for 12 weeks in the placebo-controlled period and 66 weeks in the long term extension (LTE) period… |
| Registration date | Aug 16, 2021 |
| Target size | 425 |
| Secondary IDs | NCT04888585 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: